Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EUCROSS: A Phase II Trial to Evaluate Efficacy and Safety of Crizotinib Treatment in Advanced Adenocarcinoma of the Lung Harbouring ROS1 Translocations

NCT02183870 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT02183870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02183870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EUCROSS: A Phase II Trial to Evaluate Efficacy and Safety of Crizotinib Treatment in Advanced Adenocarcinoma of the Lung Harbouring ROS1 Translocations
Lead sponsor
University of Cologne
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
February 29, 2020
Enrollment
34 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, lung cancer, nsclc